Clinical trials: Human Healthy Volunteers
- Condition Human Healthy Volunteers
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248
This is a First in Human (FIH), double-blinded, parallel-group, randomised, placebo-controlled study designed to evaluate the safety, tolerability, PK and PD of single and multiple ascending oral doses of GS-248 in healthy…
- Trial name
- NCT04036227
- Testing
- GS-248
- Where
- Sweden
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Gesynta Pharma AB
Influenza, Human
Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)
This is a phase I, double-blind, randomized, placebo-controlled trial with two groups of subjects to receive seasonal trivalent inactivated split virion influenza vaccine (A/H1N1; A/H3N2 and B strains) or placebo (phosphate…
- Trial name
- IVACFLU-S (NCT02598089)
- Testing
- Trivalent Seasonal Influenza Vaccine
- Where
- Vietnam
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Institute of Vaccines and Medical Biologicals, Vietnam
Healthy
Human Participant Study of a Prototype Multilayer Foam Dressing on Intact Skin.
The purpose of this study is to evaluate a new prototype multilayer foam dressing on healthy, intact skin. The study will find out how well the new prototype dressing stays in place as well as other dressing performance and…
- Trial name
- NCT06831448
- Testing
- Prototype dressing, Marketed dressing 1, Marketed dressing 2
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Smith & Nephew, Inc.
Safety, Pharmacokinetics, Pharmacodynamics, Food Effect
Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study
This is a phase I, randomised, single-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of AZD7986 in healthy volunteers
- Trial name
- NCT02303574
- Testing
- AZD7986, oral solution, 1 to 50 mg/mL
- Where
- United Kingdom
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Influenza Immunization, Healthy Volunteers
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
This was a phase IV, multi-center, open-label study. The study collected serum samples from children 6 months to less than (<) 9 years of age who received Fluzone Quadrivalent vaccine and adults greater than or equal to (>=) 65…
- Trial name
- NCT05050318
- Testing
- Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy Participants
A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults
The purposes of this study are: To see how the new medicine (PF-07853578) under study is tolerated. And if there are any important side effects. And, how people feel after taking single increasing amount of the medicine by mouth.
- Trial name
- NCT05890105
- Testing
- PF-07853578
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Reverse Genetic H9N2 Influenza Vaccine Study in Adults
The purpose of the study is to identify the optimal dose level of a reverse genetic (RG) reassortant H9N2 pandemic influenza vaccine for further product development.
- Trial name
- NCT01320696
- Testing
- Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine
- Where
- 5 sites in United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza Immunization, Healthy Volunteers
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older
Primary Objective: To demonstrate that high-dose quadrivalent influenza vaccine (QIV-HD) induces an immune response that is superior to the responses induced by standard-dose quadrivalent influenza vaccine (QIV-SD) for all 4…
- Trial name
- NCT04024228
- Testing
- Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD), High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation
- Where
- 17 sites in Belgium, France and 4 more
- Volunteers
- 1,539 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects
The purpose of this study is to: 1. Evaluate the safety and tolerability of KamRAB in comparison with Human rabies immune globulin (HRIG) comparator product. 2.
- Trial name
- KAMRAB-003 (NCT02040090)
- Testing
- Active rabies vaccine (US-FDA approved)
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Kamada, Ltd.
Influenza, Human
A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers
This is a study to assess the immune (antibody) response and safety of the 2013/2014 formulation of Enzira® vaccine in healthy adult volunteers aged 18 years or older.
- Trial name
- NCT01857297
- Testing
- Enzira® vaccine
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Seqirus
Muscular Dystrophies
First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect
The FTIH study with GSK3439171A will evaluate the safety of GSK3439171A in healthy subjects in order to avoid confounding factors due to the disease or concomitant drugs in patients.
- Trial name
- NCT03627494
- Testing
- GSK3439171A
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Volunteer
A Study to Examine the Effects of Minocycline Extended-Release Tablets on Sperm Production in Human Males.
Researchers want to find out how Minocycline Extended-Release Tablets affect sperm-production in healthy males. The study will include Minocycline Extended-Release Tablets, a new once-daily formulation of minocycline, compared…
- Trial name
- NCT00765336
- Testing
- minocycline extended release
- Where
- 10 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Medicis Pharmaceutical Corporation
HIV Infections
First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants
This FTIH study aims to evaluate the safety, tolerability and PK of the novel investigational Human immunodeficiency virus (HIV)-1 capsid inhibitor VH4011499 in healthy adults.
- Trial name
- NCT05393271
- Testing
- VH4011499, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Asthma
A Study to Evaluate the Safety and Use of Human Rhinovirus in Healthy and Asthmatic Participants (MK-0000-218)
The purpose of this study is to establish the safety and tolerability of Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) human rhinovirus 16 (RV16UB) in healthy and asthmatic participants, and…
- Trial name
- NCT01866306
- Testing
- RV16UB, LABA
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pharmacokinetic Bioequivalence Study in Human Healthy Volunteers
Comparative, Pharmacokinetic and Pharmacodynamic Study of Subcutaneous Injections of INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.
The study was an assessor-blind, balanced, randomized, two-treatment, two-period, single-dose, two-way crossover, comparative, pharmacokinetic (PK) and pharmacodynamic (PD) study of subcutaneous (SC) Pegfilgrastim injection (6…
- Trial name
- NCT04014062
- Testing
- INTP5, US Neulasta
- Where
- India
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Intas Pharmaceuticals, Ltd.
Norovirus Infections
Norovirus Challenge Study
This is a Phase 2b randomized, double-blind, placebo-controlled vaccination and challenge study to assess the protective efficacy of the Vaxart Norovirus vaccine (VXA-G1.1-NN).
- Trial name
- G1-1 Challenge (NCT05212168)
- Testing
- VXA-G1.1-NN, Norovirus GI.1 Norwalk Virus Inoculum
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Vaxart
Healthy Volunteers
A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults
The main aim of this study is to check how well healthy adults can tolerate TAK-881 with different dosing schedules. During the study, participants will receive one infusion of TAK-881 under the skin (subcutaneous [SC] infusion)…
- Trial name
- NCT06935266
- Testing
- TAK-881, SC Investigational Needle Sets
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy Volunteer Study
Study Investigating the Safety, Tolerability, PK and Food Effect of BEN8744.
BEN8744 is an experimental new medicine for treating inflammatory bowel diseases such as Ulcerative Colitis. The study will test single and repeated oral doses of BEN8744 or placebo.
- Trial name
- NCT06118385
- Testing
- BEN8744
- Where
- United Kingdom
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- BenevolentAI Bio
Healthy
First in Man Trial of BI 113608
The primary objective of the current study is to investigate the safety and tolerability of BI 113608 in healthy male volunteers following oral administration of single rising doses.
- Trial name
- NCT01540825
- Testing
- BI 113608
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Viral Upper Respiratory Tract Infection
A Study to Examine the Duration of Effect of PrEP-001 in Healthy Subjects Challenged With HRV-16
A study to examine the duration of effect of PrEP-001 in healthy subjects challenged with HRV-16
- Trial name
- NCT03338556
- Testing
- PrEP-001
- Where
- United Kingdom
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Prep Biopharm Limited